Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosaBruno François, Jean Chastre, Charles‐Édouard Luyt et al.|Critical Care Medicine|2012Cited by 182
Site-specific attachment to recombinant antibodies via introduced surface cysteine residuesJohn R. Adair, David J. King, Raymond J. Owens et al.|Protein Engineering Design and Selection|1990Cited by 66
Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II studyJoanne L. Casey, Richard H. J. Beǵent, RB Pedley et al.|British Journal of Cancer|2002Cited by 43
A Randomized Placebo-Controlled Safety and Pharmacodynamic Study of KB002, a Chimeric Anti-GM-CSF Monoclonal Antibody, in Patients with AsthmaNéstor A. Molfino, Geoffrey Yarranton, Philip G. Bardin et al.|Journal of Allergy and Clinical Immunology|2013Cited by 3